Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
OLMA 
Olema Pharmaceuticals Inc (OLMA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/03/2025: OLMA (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $24.38
1 Year Target Price $24.38
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 107.92% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 615.65M USD | Price to earnings Ratio - | 1Y Target Price 24.38 |
Price to earnings Ratio - | 1Y Target Price 24.38 | ||
Volume (30-day avg) 8 | Beta 2.09 | 52 Weeks Range 2.86 - 13.51 | Updated Date 11/3/2025 |
52 Weeks Range 2.86 - 13.51 | Updated Date 11/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.97 |
Earnings Date
Report Date 2025-11-11 | When - | Estimate -0.4234 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -29.87% | Return on Equity (TTM) -49.72% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 407428425 | Price to Sales(TTM) - |
Enterprise Value 407428425 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.33 | Shares Outstanding 68634329 | Shares Floating 39669956 |
Shares Outstanding 68634329 | Shares Floating 39669956 | ||
Percent Insiders 3.28 | Percent Institutions 104.73 |
Upturn AI SWOT
Olema Pharmaceuticals Inc
Company Overview
History and Background
Olema Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Founded in 2019, Olema went public in November 2020. Its focus is on therapies that address resistance mechanisms to existing cancer treatments.
Core Business Areas
- Oncology Drug Development: Research, development, and clinical trials of novel therapies for breast and other cancers, with a primary focus on endocrine therapies and combination strategies.
Leadership and Structure
Sean P. Bohen, M.D., Ph.D., is the President and Chief Executive Officer. The company has a typical biopharmaceutical organizational structure with departments focused on research, development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- OPC-5180: OPC-5180 is Olema's lead product candidate, an oral complete estrogen receptor antagonist (CERAN) in development for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. It is currently in Phase 1/2 clinical trials. Since it is in clinical stage, there is no current market share or revenue from this product. Competitors include companies developing other ER-targeted therapies, such as AstraZeneca (with endocrine therapies like Faslodex) and Radius Health (Elacestrant).
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the oncology segment, is characterized by high innovation, intense competition, and stringent regulatory oversight. There is significant demand for novel cancer therapies, especially those that address resistance to existing treatments.
Positioning
Olema is positioned as an innovator in the area of ER+ breast cancer, focusing on overcoming resistance mechanisms. Its competitive advantage lies in its unique CERAN approach and its potential to address a significant unmet need.
Total Addressable Market (TAM)
The global breast cancer therapeutics market is expected to reach ~$30 billion by 2030. Olema's positioning with OPC-5180, targeting ER+ HER2- breast cancer, allows them to address a large subset of this TAM, dependent on clinical trial success and market penetration.
Upturn SWOT Analysis
Strengths
- Novel CERAN technology with potential to overcome resistance
- Experienced management team
- Strong financial position (from IPO and subsequent financings)
- Focused on a significant unmet medical need (ER+ HER2- breast cancer)
Weaknesses
- Early-stage clinical development (high risk of failure)
- Dependence on a single lead product candidate
- Competition from established pharmaceutical companies
- Unproven commercialization capabilities
Opportunities
- Positive clinical trial results for OPC-5180
- Expansion of pipeline through further research and development
- Partnerships or acquisitions to accelerate development and commercialization
- Potential for use of CERAN technology in other cancers
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies developing similar therapies
- Changes in the healthcare landscape and reimbursement policies
Competitors and Market Share
Key Competitors
- AZN
- RAD
Competitive Landscape
Olema faces competition from established pharmaceutical companies with existing breast cancer therapies and from other companies developing novel ER-targeted therapies. Its advantage lies in its CERAN technology, which has the potential to overcome resistance to existing treatments. Since the drug is still in trials, the market share is close to zero (small trials). The competitor numbers are estimations for the overall ER+ HER2- treatment market.
Growth Trajectory and Initiatives
Historical Growth: Olema's historical growth is characterized by rapid expansion of its research and development activities since its founding.
Future Projections: Future growth is highly dependent on the success of OPC-5180 in clinical trials. Analyst estimates vary widely but generally project significant revenue potential if OPC-5180 is approved.
Recent Initiatives: Recent initiatives include advancing OPC-5180 through clinical trials, expanding the research and development team, and exploring potential partnerships.
Summary
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focusing on developing novel therapies for women's cancers. Its lead product candidate, OPC-5180, is in early clinical trials. While it has a strong cash position and novel technology, it faces significant risks associated with clinical development and competition from larger companies. Its future success heavily relies on the positive outcomes of its clinical trials and effectively commercializing successful therapies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Olema Pharmaceuticals Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. The accuracy and completeness of the data cannot be guaranteed. Investment decisions should be made based on thorough research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Olema Pharmaceuticals Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2020-11-19 | President, CEO & Director Dr. Sean P. Bohen M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 116 | Website https://olema.com |
Full time employees 116 | Website https://olema.com | ||
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.